Natera stock: Management targets over 6 billion by 2029
Published on 11/20/2026 at 16:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat management highlighted
- Signatera remains Natera's central growth engine, with reimbursement expansion supporting the pricing outlook.
- Management expects nine MolDX applications to move through decisions that typically take nine to 12 months.
- The FIND-CRC colorectal cancer study is expected to provide a major future market catalyst.
Natera stock: Management targets more than 6 billion US dollars in revenue by 2029. The company presented the longer-term ambition at the Jefferies Global Healthcare Conference on November 18, according to a Reuters transcript published by Investing.com.
Signatera drives the plan
Chief Financial Officer Mike Brophy said revenue grew 42 percent year over year excluding true-ups, while full-year 2026 guidance was reset to above 3 billion US dollars. Signatera remains the main growth engine, with an average selling price of about 1,290 US dollars and a target of 1,450 US dollars by 2029.
Management sees an annual Signatera opportunity of about 20 billion US dollars and said roughly 1 billion US dollars has been reached so far. The path toward higher pricing depends on additional reimbursement, Medicare Advantage compliance, commercial payer coverage in biomarker states and possible inclusion in NCCN clinical practice guidelines.
Reimbursement remains pivotal
Natera has nine further MolDX coverage applications in process. Management said decisions typically take nine to 12 months, making reimbursement timing a material execution factor for future volume and pricing.
The company also highlighted Signatera Genome, which uses whole-genome sequencing and phased or structural variants. Management expects current cost-of-goods pressure for the newer version to normalize over a couple of quarters, while prospective outcomes studies are scheduled to provide further evidence in 2027 and 2028.
Early detection adds potential
The FIND-CRC study is enrolling more than 25,000 patients and is expected to provide results next year. Natera said blood-based colorectal cancer screening could eventually address 13 million to 14 million Americans annually, although commercial scale-up depends on clinical results and reimbursement.
Natera stock last traded at 257.80 euros on Lang & Schwarz at 16:03 CET on Friday, November 20, 2026.
Natera Inc.
- Company: Natera Inc.
- ISIN: US6323071042
- Ticker: NTRA
- Trading venue: Lang & Schwarz
- Last quoted price: 257.80 euros on Friday, November 20, 2026, at 16:03 CET
Investors can follow the US market backdrop through current market reports.
